developed a method to measure both CAG-repeat lengths and gene expression in individual brain cells of six deceased people with Huntington’s disease. The researchers analysed tissue from a brain ...

A survey conducted in Canada examined the prevalence of perceived genetic discrimination against patients with Huntington disease. The respondents reported discrimination not only by insurance or ...

uniQure has presented new results from its phase 1/2 study of its gene therapy for Huntington’s disease that it said were positive, although investors are far from convinced by the data.

Huntington's disease (HD) is an inherited neurodegenerative disease caused by an abnormal expansion of a CAG repeat in the huntingtin ( HTT) gene. The primary genetic determinant of the age at ...

A 14-year study tracking NfL levels in people with the HD gene shows this tiny protein can signal disease progression many ...

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

According to the University of California San Francisco, Huntington’s disease affects one in every 10,000 to 20,000 people in ...

“As someone who has devoted my career to Huntington’s disease (HD), I am tremendously excited about the advancements we've made in developing a gene therapy that targets the somatic ...

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO ...

The Missouri Chapter of the Huntington's Disease Society of America will host a Team Hope walk Saturday, April 12, at Jackson ...

uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past ...